Search Result

Results for "

ATP-binding

" in MedChemExpress (MCE) Product Catalog:

By Targets:	P-glycoprotein (1) Akt (2) Antibiotic (2) Apoptosis (14) ATM/ATR (1) Aurora Kinase (1) Autophagy (8) Bacterial (7) Bcr-Abl (3) BCRP (4) BMX Kinase (1) Btk (4) c-Fms (2) c-Kit (3) c-Met/HGFR (5) Casein Kinase (1) CDK (1) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (1) Drug Metabolite (1) EGFR (8) Endogenous Metabolite (1) Eukaryotic Initiation Factor (eIF) (1) FAK (1) FGFR (2) FLT3 (3) Fluorescent Dye (1) GSK-3 (2) HSP (2) IRE1 (3) Isotope-Labeled Compounds (2) JAK (3) Leukotriene Receptor (2) LIM Kinase (LIMK) (1) LPL Receptor (2) MAP3K (2) MEK (1) Microtubule/Tubulin (1) mTOR (1) NOD-like Receptor (NLR) (1) P2Y Receptor (1) p38 MAPK (2) PAK (1) Parasite (2) PDGFR (4) Phosphodiesterase (PDE) (1) PI3K (2) PI4K (1) Pim (1) Potassium Channel (3) Raf (1) Reverse Transcriptase (1) ROS Kinase (1) SARS-CoV (3) Sirtuin (1) Sodium Channel (1) Src (1) STAT (2) Syk (2) Tie (1) Trk Receptor (2) VEGFR (1)
By Research Areas:	Cancer (53) Cardiovascular Disease (6) Endocrinology (1) Infection (9) Inflammation/Immunology (19) Metabolic Disease (3) Neurological Disease (6)

By Targets:

P-glycoprotein (1)

Akt (2)

Antibiotic (2)

Apoptosis (14)

ATM/ATR (1)

Aurora Kinase (1)

Autophagy (8)

Bacterial (7)

Bcr-Abl (3)

BCRP (4)

BMX Kinase (1)

Btk (4)

c-Fms (2)

c-Kit (3)

c-Met/HGFR (5)

Casein Kinase (1)

CDK (1)

Checkpoint Kinase (Chk) (1)

Cholinesterase (ChE) (1)

Drug Metabolite (1)

EGFR (8)

Endogenous Metabolite (1)

Eukaryotic Initiation Factor (eIF) (1)

FAK (1)

FGFR (2)

FLT3 (3)

Fluorescent Dye (1)

GSK-3 (2)

HSP (2)

IRE1 (3)

Isotope-Labeled Compounds (2)

JAK (3)

Leukotriene Receptor (2)

LIM Kinase (LIMK) (1)

LPL Receptor (2)

MAP3K (2)

MEK (1)

Microtubule/Tubulin (1)

mTOR (1)

NOD-like Receptor (NLR) (1)

P2Y Receptor (1)

p38 MAPK (2)

PAK (1)

Parasite (2)

PDGFR (4)

Phosphodiesterase (PDE) (1)

PI3K (2)

PI4K (1)

Pim (1)

Potassium Channel (3)

Raf (1)

Reverse Transcriptase (1)

ROS Kinase (1)

SARS-CoV (3)

Sirtuin (1)

Sodium Channel (1)

Src (1)

STAT (2)

Syk (2)

Tie (1)

Trk Receptor (2)

VEGFR (1)

By Research Areas:

Cancer (53)

Cardiovascular Disease (6)

Endocrinology (1)

Infection (9)

Inflammation/Immunology (19)

Metabolic Disease (3)

Neurological Disease (6)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Vorolanib CM082; X-82	VEGFR PDGFR	Cardiovascular Disease Cancer
Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895) .

3BrB-PP1	Others	Neurological Disease Cancer
3BrB-PP1 is an ATP-competitive analog. 3BrB-PP1 can specifically inhibit the activity of protein kinase with mutations in the ATP-binding pocket (mutation of Thr97 within Sty1’s ATP-binding pocket) .

FGFR1 inhibitor-8	FGFR	Cancer
FGFR1 inhibitor-8 (Compound 9) is a FGFR1 inhibitor (IC₅₀s: 0.5 nM). FGFR1 inhibitor-8 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-8 has anticancer activity .

FGFR1 inhibitor-9	FGFR	Cancer
FGFR1 inhibitor-9 (Compound 7) is an FGFR1 inhibitor (IC₅₀s: 0.85 nM). FGFR1 inhibitor-9 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-9 has anticancer activity .

BMS-243117	Src	Cancer
BMS-243117 is a potent, and selective benzothiazole based p56 ^Lck inhibitor with an IC₅₀ of 4 nM. BMS-243117 inhibits anti-CD3/anti-CD28 induced PBL proliferation with an IC₅₀ of 1.1 μM. BMS-243117 binds in an extended conformation to the ATP-binding site of Lck .

ATR kinase substrate peptide	ATM/ATR	Cancer
ATR kinase substrate peptide (compound 45) is a potent and selective inhibitor of ATR (Ataxia Telangiectasia and Rad3 related) protein kinase (K_i=6 nM). ATR kinase substrate peptide inhibits ATR activity by competing with ATR kinase ATP-binding sites to block ATR mediated signaling. ATR kinase substrate peptide can be used to study the role of ATR kinase in DNA damage response .

Macbecin Macbecin I; NSC 330499	HSP	Cancer
Macbecin is a stable HSP90 inhibitor by binding to the ATP-binding site with an IC₅₀ of 2 μM and a K_d of 0.24 μM. Macbecin exhibits antitumor and cytocidal activities .

TRK-IN-22	Trk Receptor	Others
TRK-IN-22 (compound 11) is a TRK inhibitor. TRK-IN-22 (compound 11), a typical type I inhibitor, covers the ATP-binding pocket of TRKA .

SC99	STAT JAK Apoptosis	Cardiovascular Disease Cancer
SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling. SC99 inhibits platelet activation, aggregation and displays potent anti-myeloma, anti-thrombotic activities .

R-10015	LIM Kinase (LIMK) Reverse Transcriptase	Infection
R-10015, a broad-spectrum antiviral compound for HIV infection, acts as a potent and selective inhibitor of LIM domain kinase (LIMK) and binds to the ATP-binding pocket, with an IC₅₀ of 38 nM for human LIMK1 .

Aloisine B	CDK	Others
Aloisine B (compound 9) is a cyclin-dependent kinase (CDK) inhibitor. Aloisine B inhibits cell proliferation by arresting cells in both G1 and G2 via competing with ATP-binding pocket .

ASK1-IN-4	MAP3K Apoptosis	Inflammation/Immunology Cancer
ASK1-IN-4 (Compound 17) is an ASK1 inhibitor (IC₅₀=0.2 μM). ASK1-IN-4 interacts with ATP-binding site of ASK1 .

E1231 1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one	Sirtuin	Cardiovascular Disease
E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC₅₀=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (K_D=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE ^-/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases .

PIM1-IN-2	Pim	Cancer
PIM1-IN-2 is a potent and ATP competitive Pim-1 inhibitor with a K_i of 91 nM. PIM1-IN-2 targets the ATP-binding kinase hinge region not by forming classical hydrogen bonds .

KY-04031	PAK	Cancer
KY-04031 is a potent PAK4 inhibitor with IC₅₀ of 0.79 μM. KY-04031 binds to the ATP-binding pocket of PAK4. KY-04031 blocks tumor cell growth and invasion .

PV1115	Checkpoint Kinase (Chk)	Cancer
PV1115 is a potent and highly selective Chk2 inhibitor with an IC₅₀ of 0.14 nM, 66000 nM, >100000 nM for Chk2, Chk1 and RSK2, respectively. PV1115 is situated within the ATP-binding pocket of Chk2 .

TNP	Others	Cancer
TNP is a cell-permeable inhibitor of IP6K1 and IP3K, with IC₅₀ values of 0.55 µM and 10.2 µM for IP3K, respectively. TNP binds to the ATP-binding sites of both enzymes .

G092	Bacterial	Infection
G092 is a potent inhibitor of MsbA. MsbA is an ABC transporter. Transmembrane ATP-binding cassette (ABC) transporters are crucial cellular machines that move molecules small and large across membranes. G092 has the potential for the research of antimicrobial agents .

Bozitinib 1 Publications Verification PLB-1001; CBT-101; Vebreltinib	c-Met/HGFR	Cancer
Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily .

Ko 143 30+ Cited Publications	BCRP	Cancer
Ko 143 is a potent and selective ATP-binding cassette subfamily G member 2 (ABCG2/BCRP) inhibitor. Ko 143 displays >200-fold selectivity over P-gp and MRP-1 transporters .

CY-09 25+ Cited Publications	NOD-like Receptor (NLR)	Inflammation/Immunology
CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .

PAIR2	IRE1	Cancer
PAIR2 is a potent and selective partial antagonist of IRE1α RNase. PAIR2 can completely occupy IRE1α’s ATP-binding site in cells and block the ability of a potent KIRA to inhibit XBP1 splicing .

APY29 5+ Cited Publications	IRE1	Cancer
APY29, an ATP-competitive inhibitor, is an allosteric modulator of IRE1α which inhibits IRE1α autophosphorylation by binding to the ATP-binding pocket with IC₅₀ of 280 nM. APY29 acts as a ligand that allosterically activates IRE1α adjacent RNase domain .

Kyoto probe 1	Fluorescent Dye	Others
Kyoto probe 1 is a hiPSCs fluorescent probe. Kyoto probe 1 selectively labels human pluripotent stem cells. Kyoto probe 1 is primarily explained by the distinct expression patterns of ATP-binding cassette (ABC) transporters by hiPS cells and differentiated cells .

Zipalertinib 1 Publications Verification TAS6417; CLN-081	EGFR Apoptosis	Cancer
Zipalertinib (TAS6417; CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC₅₀ values ranging from 1.1-8.0 nM .

ML230 CID44640177; SID 88095709	BCRP	Cancer
ML230 (CID44640177; SID 88095709) is a selective inhibitor of ATP-binding cassette (ABC) transporter ABCG2, and 36-fold selective for ABCG2 over ABCB1 with EC₅₀s values of 0.13 μM and 4.65 μM, respectively .

Aurora kinase inhibitor-3	Aurora Kinase	Others
Aurora kinase inhibitor-3 is a strong and selective Aurora A kinase inhibitor with an IC₅₀ of 42 nM, and weakly inhibits EGFR with an IC₅₀ of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket .

KIRA9	IRE1 Apoptosis	Others
KIRA9 is a potent IRE1 inhibitor (IC₅₀=4.8 μM in INS-1 cells). KIRA9 is able to fully engage the ATP-binding site of IRE1α. KIRA9 can block ER-localized mRNA decay and apoptosis .

G907 1 Publications Verification	Bacterial	Infection
G907 is a selective antagonist of ATP-binding cassette (ABC) transporter MsbA with anti-microbial activity. G907 inhibits E. coli MsbA with an IC₅₀ value of 18 nM. G907 traps MsbA in an inward-facing, lipopolysaccharide-bound conformation by wedging into an architecturally conserved transmembrane pocket .

PD318088 1 Publications Verification	MEK	Cancer
PD318088 is a potent, allosteric and non-ATP competitive MEK1/2 inhibitor, an analog of PD184352 (HY-50295). PD318088 binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. PD318088 can be used for cancer research .

NF340	P2Y Receptor	Inflammation/Immunology
NF340 is a potent and selective P2Y11 receptor antagonist. NF340 inhibits the activity of P2Y11R by completely combining with ATP-binding amino acid residues. NF340 ameliorates inflammation in human fibroblast-like synoviocytes and can be used for rheumatoid arthritis research .

SIQ17	EGFR	Cancer
SIQ17 is an EGFR inhibitor that inhibits its activity by occupying the ATP-binding site, with IC₅₀ of 0.62 nM. SIQ17 shows more effective EGFR-TK inhibitory activity compared to the known inhibitor Erlotinib (HY-50896) (IC₅₀ of ∼20 nM). SIQ17 can be used for cancer research

MY-5445	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology Cancer
MY-5445 is a specific inhibitor of the cyclic GMP phosphodiesterase, phosphodiesterase type 5 (PDE5), with a K_i of 1.3 μM. MY-5445 inhibits human platelet aggregation. MY-5445 is a selective modulator of ATP-binding cassette (ABC) transporter ABCG2, with anti-proliferative effect .

DBPR112	EGFR	Cancer
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC₅₀s of 15 nM and 48 nM for EGFR ^WT and EGFR ^L858R/T790M, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy .

SR-4133	Casein Kinase	Cancer
SR-4133 is a potent and highly CK1ε selective inhibitor with an IC₅₀ of 58 nM. SR-4133 binds to the ATP-binding site of CK1ε. SR-4133 displays nanomolar growth inhibition of bladder cancer cells, and inhibits the phosphorylation of 4E-BP1 .

IDD-8E	Bacterial	Infection
IDD-8E is an effective anti-pseudomonal agent (MIC =4.4 µM ) with no cytotoxicity. IDD-8E shows significant pseudomonal killing and disruption of pseudomonal biofilm. IDD-8E binds to the ATP-binding pocket of WaaP and also inhibits other ESKAPE pathogens.

All-trans-retinal	Endogenous Metabolite Apoptosis	Metabolic Disease
All-trans-retinal is an vitamin A metabolite in the retina, and is produced following photo-isomerization of the visual chromophore 11-cis-Retinal. All-trans-retinal is cleared from photoreceptors by ATP-binding cassette transporter (ABCA4) and all-trans-retinol dehydrogenase (RDH). All-trans-retinal induces Bax activation via DNA damage to mediate retinal cell apoptosis .

TTT-28	P-glycoprotein	Cancer
TTT-28 is a synthesized thiazole-valine peptidomimetic, a novel selective inhibitor of ABCB1 (P-gp/MDR1) with high efficacy and low toxicity, which reverses the ATP-binding cassette sub-family B member 1 (ABCB1)-mediated multidrug resistance (MDR) by selectively blocking the efflux function of ABCB1 .

FIKK9.1-IN-1	Parasite	Infection
FIKK9.1-IN-1 (Compound 1) is a FIKK9.1 inhibitor. FIKK9.1-IN-1 interacts with the ATP?binding residues in FIKK9.1. FIKK9.1-IN-1 is an antimalarial agent (IC₅₀: 2.68 μg/mL) and disrupts the parasite life cycle and leads to the death of parasites .

PCI 29732 3 Publications Verification	Btk BCRP	Inflammation/Immunology
PCI 29732 is a potent, orally active, reversible BTK inhibitor with K_i ^app values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase. PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 .

Dalmelitinib	c-Met/HGFR	Cancer
Dalmelitinib is an orally active selective c-Met kinase inhibitor (IC₅₀: 2.9 nM) that binds to the ATP-binding region of c-Met. Dalmelitinib induces the phosphorylation of MET, partially or completely inhibits the phosphorylation of AKT and ERK. Dalmelitinib potently inhibits cancer cell (c-Met oncogene amplification) proliferation, and is used for the research of cancers like human non-small cell lung cancer (NSCLC) .

A-803467 1 Publications Verification	Sodium Channel	Neurological Disease Inflammation/Immunology
A-803467 is a potent and selective tetrodotoxin-resistant Na_v1.8 sodium channel blocker (IC₅₀=8 nM). A-803467 has shown significant anti-nociception in neuropathic and inflammatory pain models. A-803467 enhances the chemosensitivity of conventional anticancer agents through interaction with the ATP-binding cassette subfamily G member 2 (ABCG2) transporter .

Acalabrutinib-d3 ACP-196-d₃	Isotope-Labeled Compounds	Others
Acalabrutinib-d₃ (ACP-196-d₃) is the deuterated form of Acalabrutinib (HY-17600). Acalabrutinib (ACP-196) is an orally active, irreversible, highly selective second-generation BTK inhibitor. Acalabrutinib covalently binds to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib shows strong targeting and efficacy in mouse models of chronic lymphocytic leukemia (CLL).

MsbA-IN-6	Antibiotic Bacterial	Infection
MsbA-IN-6 is a potent inhibitor of MsbA. MsbA-IN-6 is an antibiotic. Gram-negative ATP-binding cassette (ABC) transporter MsbA, an essential inner membrane protein, transports lipopolysaccharide from the inner leaflet to the periplasmic face of the inner membrane. MsbA-IN-6 kills Escherichia coli through inhibition of its ATPase and transport activity, with no loss of activity against clinical multidrug-resistant strains .

TX1-85-1 1 Publications Verification	EGFR	Cancer
TX1-85-1 is an irreversible Her3 (ErbB3) inhibitor with an IC₅₀ of 23 nM. TX1-85-1 is also the first selective Her3 ligand, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling .

Acalabrutinib 20+ Cited Publications ACP-196	Btk	Cancer
Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL) . Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name	Target	Research Area

HY-P10280

ATR kinase substrate peptide	ATM/ATR	Cancer
ATR kinase substrate peptide (compound 45) is a potent and selective inhibitor of ATR (Ataxia Telangiectasia and Rad3 related) protein kinase (K_i=6 nM). ATR kinase substrate peptide inhibits ATR activity by competing with ATR kinase ATP-binding sites to block ATR mediated signaling. ATR kinase substrate peptide can be used to study the role of ATR kinase in DNA damage response .

Species:	Human (6)
Tag:	GFP (3) His (6) Strep (3) Tag Free (1) Trx (1)
Source:	HEK293 (3) E. coli Cell-free (1) E. coli (4)

Cat. No.	Compare	Product Name	Species	Source

HY-P7621

	ABCB5 Protein, Human (Trx) rHuABCB5, N-Trx; ATP-binding cassette sub-family B member 5; P-glycoprotein ABCB5; ABCB5	Human	E. coli
	ABCB5, N-Trx Protein, Human is a plasma membrane-spanning protein that in humans is encoded by the ABCB5 gene. ABCB5 is an ABC transporter and P-glycoprotein family member principally expressed in physiological skin and human malignant melanoma.

HY-P701354

	ABCC4 Protein, Human (HEK293, GFP, Strep, His) ABCC4; ATP-binding cassette sub-family C member 4; MRP/cMOAT-related ABC transporter; Multi-specific organic anion transporter B; MOAT-B; Multidrug resistance-associated protein 4	Human	HEK293
	ABCC4 Protein, an ATP-binding cassette (ABC) family member, actively transports endogenous compounds (cAMP, cGMP, bile acids) and xenobiotics from cells. Its versatility extends to glutathione conjugates (LTC4, LTB4) and drug metabolites, mediating cotransport of bile acids with reduced glutathione. ABCC4's function includes resistance to anticancer agents like methotrexate, highlighting its role in cellular communication and drug transport. ABCC4 Protein, Human (HEK293, GFP, Strep, His) is the recombinant human-derived ABCC4 protein, expressed by HEK293 , with C-10*His, C-GFP, C-Strep labeled tag. The total length of ABCC4 Protein, Human (HEK293, GFP, Strep, His) is 1325 a.a., .

HY-P72012

	ABCD1 Protein, Human (Cell-Free, His) ABC42; Abcd1; ABCD1_HUMAN; Adrenoleukodystrophy protein; ALD; Aldgh; ALDP; AMN; ATP binding cassette; sub family D ALD; ; member 1; ATP-binding cassette sub-family D member 1; OTTHUMP00000025960; OTTMUSP00000019283; RGD1562128; RP23 373N8.2; X linked adrenoleukodystrophy ALD; gene homolog	Human	E. coli Cell-free
	ABCD1, Human (His) is one of the four ATP-binding cassette (ABC) proteins in subfamily D. Dysfunction of ABCD1 causes neurodegenerative disorder X-linked adrenoleukodystrophy (X-ALD).

HY-P701355

	bABCC1 Protein, Human (HEK293, GFP, Strep, His) ABCC1; Multidrug resistance-associated protein 1; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter	Human	HEK293
	The bABCC1 protein plays a key role in cellular physiology, mediating the ATP-dependent export of a variety of substrates, including drugs and organic anions. Notably, it confers resistance to anticancer drugs, actively reducing their intracellular accumulation. bABCC1 Protein, Human (HEK293, GFP, Strep, His) is the recombinant human-derived bABCC1 protein, expressed by HEK293 , with C-10*His, C-GFP, C-Strep labeled tag. The total length of bABCC1 Protein, Human (HEK293, GFP, Strep, His) is 1530 a.a., .

HY-P701356

	bABCC1 Protein, Human (HEK293, E1454Q, GFP, Strep, His) ABCC1; Multidrug resistance-associated protein 1; ATP-binding cassette sub-family C member 1; Glutathione-S-conjugate-translocating ATPase ABCC1; Leukotriene C(4) transporter; LTC4 transporter	Human	HEK293
	The bABCC1 protein plays a key role in cellular physiology, mediating the ATP-dependent export of a variety of substrates, including drugs and organic anions. Notably, it confers resistance to anticancer drugs, actively reducing their intracellular accumulation. bABCC1 Protein, Human (HEK293, E1454Q, GFP, Strep, His) is the recombinant human-derived bABCC1 protein, expressed by HEK293 , with C-10*His, C-GFP, C-Strep labeled tag and E1454Q, , , , mutation. The total length of bABCC1 Protein, Human (HEK293, E1454Q, GFP, Strep, His) is 1530 a.a., .

HY-P72069

	ABCC1 Protein, Human (His) ABC 29; ABC29; ABCC 1; ABCC; Abcc1; ATP binding cassette sub family C CFTR/MRP; member 1; ATP binding cassette sub-family C member 1; ATP binding cassette subfamily C member 1; ATP binding cassette transporter variant ABCC1delta ex13; ATP binding cassette transporter variant ABCC1delta ex13&14; ATP binding cassette transporter variant ABCC1delta ex25; ATP binding cassette transporter variant ABCC1delta ex25&26; ATP binding cassette, sub-family C CFTR/MRP; , member 1; ATP-binding cassette sub-family C member 1; DKFZp686N04233; DKFZp781G125; GS X; GSX; Leukotriene C4; transporter; LTC4 transporter; MRP 1; MRP; MRP1; MRP1_HUMAN; Multidrug resistance associated protein 1; Multidrug resistance protein; Multidrug resistance-associated protein 1; Multiple drug resistance associated protein; Multiple drug resistance protein 1	Human	E. coli
	ABCC1, Human (His) is a multitasking ATP-binding cassette (ABC) transporter. ABCC1, Human plays a part in inflammatory and other immunological diseases, age-related macular degeneration, cardiovascular disease, and certain neurological disorders as well as tumor progression.

HY-P701867

	ClpC1 NTD Protein, Mycobacterium tuberculosis clpC1; ATP-dependent Clp protease ATP-binding subunit ClpC1	Others	E. coli
	ClpC1 NTD Protein, the ATP-dependent specificity component of the Clp protease, directs the protease to specific substrates and exhibits chaperone functions independently of ClpP. It plays a crucial role in the targeted degradation of substrates, such as the anti-sigma-E factor RseA, in the presence of ClpP2. ClpC1 NTD Protein, Mycobacterium tuberculosis is the recombinant ClpC1 NTD protein, expressed by E. coli , with tag free. The total length of ClpC1 NTD Protein, Mycobacterium tuberculosis is 145 a.a., .

HY-P701868

	ClpC1 NTD Protein, Mycobacterium tuberculosis (His) clpC1; ATP-dependent Clp protease ATP-binding subunit ClpC1	Others	E. coli
	ClpC1 NTD Protein, the ATP-dependent specificity component of the Clp protease, directs the protease to specific substrates and exhibits chaperone functions independently of ClpP. It plays a crucial role in the targeted degradation of substrates, such as the anti-sigma-E factor RseA, in the presence of ClpP2. ClpC1 NTD Protein, Mycobacterium tuberculosis (His) is the recombinant ClpC1 NTD protein, expressed by E. coli , with N-6*His labeled tag. The total length of ClpC1 NTD Protein, Mycobacterium tuberculosis (His) is 145 a.a., .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80772

	P Glycoprotein Antibody p-pg; ABCB1; MDR1; PGY1; Multidrug resistance protein 1; ATP-binding cassette sub-family B member 1; P-glycoprotein 1; CD antigen CD243	WB	Human
	P Glycoprotein Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 141 kDa, targeting to P Glycoprotein. It can be used for WB assays with tag free, in the background of Human.

HY-P82967

	ABCF1 Antibody (YA2712) ABC27; ABC50; ABCF1; ATP-binding cassette 50; ATP-binding cassette 50 (TNF-alpha stimulated); TNF-alpha-stimulated ABC protein	WB, IHC-P, ICC/IF	Human, Rat
	ABCF1 Antibody (YA2712) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2712), targeting ABCF1, with a predicted molecular weight of 96 kDa (observed band size: 96 kDa). ABCF1 Antibody (YA2712) can be used for WB, IHC-P, ICC/IF experiment in human, rat background.

HY-P82096

	ABCG1 Antibody (YA1841) ATP-binding cassette transporter 8; White protein homolog; ABC8; WHT1; ABCG1; ABC transporter 8; WHITE1	WB	Human
	ABCG1 Antibody (YA1841) is a biotin-conjugated non-conjugated IgG antibody, targeting ABCG1, with a predicted molecular weight of 76 kDa (observed band size: 100 kDa). ABCG1 Antibody (YA1841) can be used for WB experiment in human background.

HY-P81118

	MRP2/ABCC2 Antibody multidrug resistance-associated protein2; ABC30; ABCC2; ATP binding cassette sub family C (CFTR/MRP) member 2; ATP binding cassette subfamily C member 2; Canalicular multidrug resistance protein; Canalicular multispecific organic anion transporter 1; CMOAT; CMOAT1; cMRP; DJS; KIAA1010; MRP 2; MRP-2; MRP2; Multidrug resistance associated protein 2; MRP2_HUMAN; ATP-binding cassette sub-family C member 2; Multidrug resistance-associated protein 2.	WB, ELISA, IHC-P, IHC-F, ICC/IF	Human, Mouse, Rat,
	MRP2/ABCC2 Antibody is an unconjugated, approximately 174 kDa, rabbit-derived, anti-MRP2/ABCC2 polyclonal antibody. MRP2/ABCC2 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, background without labeling.

HY-P80527

	ABCB5 Antibody (YA836) ABCB5 P-gp; ATP binding cassette sub family B (MDR/TAP) member 5; P glycoprotein ABCB5	WB, ICC/IF	Human
	ABCB5 Antibody (YA836) is a non-conjugated and Mouse origined monoclonal antibody about 139 kDa, targeting to ABCB5 (8D2). It can be used for WB,ICC/IF assays with tag free, in the background of Human.

HY-P83069

	CLPX Antibody (YA2814) ATP-dependent Clp protease ATP-binding subunit clpX-like; mitochondrial; CLPX	WB, ICC/IF	Human, Mouse, Rat, Hamster
	CLPX Antibody (YA2814) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2814), targeting CLPX, with a predicted molecular weight of 69 kDa (observed band size: 69 kDa). CLPX Antibody (YA2814) can be used for WB, ICC/IF experiment in human, mouse, rat, hamster background.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks